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Abstract 
The past decade has witnessed an exponential increase in the number of publications 
referring to extracellular vesicles (EVs). For many years considered to be extracellular 
debris, EVs are now seen as novel mediators of endocrine signalling via cell-to-cell 
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communication. With the capability of transferring proteins and nucleic acids from one cell to 
another, they have become an attractive focus of research for different pathological settings 
and are now regarded as both mediators and biomarkers of disease including cardio-
metabolic disease. They also offer therapeutic potential as signalling agents capable of 
targeting tissues or cells with specific peptides or miRNAs. In this review, we focus on the 
role that microvesicles and exosomes, the two most studied classes of EV, have in diabetes, 
cardiovascular disease, endothelial dysfunction, coagulopathies and polycystic ovary 
syndrome. We also provide an overview of current developments in microvesicle/exosome 
isolation techniques from plasma and other fluids, comparing different available commercial 
and non-commercial methods. We describe different techniques for their optical/biochemical 
characterization and quantitation. We also review the signalling pathways that exosomes 
and microvesicles activate in target cells and provide some insight into their use as 
biomarkers or potential therapeutic agents. In summary, we give an updated focus on the 
role that these exciting novel nanoparticles offer for the endocrine community. 
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Introduction 
It is well established that patients with metabolic diseases, in particular insulin resistance 
and type two diabetes mellitus (T2DM), are more than twice as likely to develop accelerated 
cardiovascular disease (CVD) including atherosclerosis, stroke and coronary artery disease 
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(reviewed in (Rask-Madsen and King 2013)). Coronary artery disease is a major cause of 
morbidity and mortality worldwide, and is a leading cause of death in T2DM, with excess risk 
of fatality in women compared to men (Peters, et al. 2014). Extensive coronary artery 
disease can result in myocardial infarction, severe loss of cardiac function, and subsequently 
lead to the development of heart failure (Hausenloy and Yellon 2013). A cluster of risk 
factors have recently been defined by the American Diabetes Association and the American 
College of Cardiology Foundation as reliable indicators of a patient’s risk for T2DM and 
CVD, and has been defined as cardiometabolic risk (CMR; (Brunzell, et al. 2008)). These 
risks include obesity, hyperglycemia, hypertension, insulin resistance and dyslipidemia.  The 
presence of secondary cardiovascular disease in patients with IR or T2DM may be referred 
to as cardio-metabolic disease (CMD). Given its increasing prevalence and severe 
consequences, new approaches are needed to diagnose and treat CMD.  
Extracellular vesicles (EVs) are small (50 nm to 2 µm) vesicles released from the surface of 
many different cell types into different bodily fluids, including plasma, milk, saliva, sweat, 
tears, semen and urine. There are several classes of EV, including exosomes, microvesicles 
(MV) and apoptotic bodies, which are produced by different mechanisms. Attracting perhaps 
the most attention recently have been exosomes (50-100 nm), a homogenous population of 
EV which are released from cells when multivesicular bodies (MVB; sometimes called 
multivesicular endosomes, MVE) fuse with the plasma membrane in a highly regulated 
process and release their contents. Cells can also produce a more heterogeneous 
population of EVs up to 2 µm in diameter called microvesicles (MVs), which are formed by 
budding and shedding of the cell membrane, a process that involves calcium dependent 
signalling and enzyme activity. Cells undergoing apoptosis also typically release EV of 1-5 
μm in diameter which are referred to as apoptotic bodies (Colombo, et al. 2014; Dignat-
George and Boulanger 2011; van der Pol, et al. 2012) (Figure 1).  
In some literature, MVs isolated by centrifugation are referred to as “microparticles”, 
particularly those isolated from platelets or endothelial cells. For clarity, this review will refer 
to EVs simply as exosomes or MV on the basis of the mechanism of their cellular production 
and their size range - an approach that has been taken by others (Thery, et al. 2009), with 
the caveat that most isolation methods do not provide a pure populations of vesicles. It is 
important to note that the size ranges of EVs may overlap and in particular, the size of 
microvesicles could overlap with the exosomal size range. Where a mixture of exosomes 
and MV is likely, for example when plasma vesicles are isolated by high speed (~100,000 g) 
ultracentrifugation, we refer to them more broadly as EV. These EV are sometimes also 
referred to as “exosome-like vesicles”. 
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One of the characteristic markers of all EVs is the presence on the outer surface of 
phosphatidyl serine (PS), due to loss of membrane asymmetry during blebbing (apoptotic 
bodies) or budding (MV) and inward folding of the membrane during vesicle formation in 
MVBs (exosomes). This can be identified by binding of labelled annexin V, a reagent often 
used for flow cytometric analysis of apoptotic cells. However, more recently several groups 
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have identified MVs lacking phosphatidyl serine (PS) on the outer membrane, suggesting 
that this is not essential for MV formation (Hou, et al. 2014; Larson, et al. 2012).  
Both exosomes and microvesicles characteristically carry a cargo, which they are able to 
deliver to cells in remote locations. The cargo can include genetic material such as mRNA, 
microRNA (miRNA) or even small amounts of DNA (Moldovan, et al. 2013), and proteins 
including transcription factors, cytokines and growth factors, have also been described. 
Importantly, MVs also carry cellular receptors and transmembrane proteins on their surface 
characteristic of the cells from which they were released. This aids in their identification but 
also means that they can interact with specific target cells instigating signalling cascades via 
receptor interactions (rececrine signalling – akin to cell-cell interactions) and also increasing 
specificity of cargo delivery. On the other hand, exosomes are characteristically decorated 
with markers including Alix, HSP70, and the tetraspanins CD9 and CD63, which may be 
associated with beta-2 integrin binding and intercellular communication. Although these are 
commonly used as markers of exosomes, they are not exclusive to exosomes and may be 
found on other EVs. Furthermore, not all EVs express CD63 and different sub-populations of 
exosomes may express different markers (Thery et al. 2009). It is important to consider that 
exosomes do not necessarily express the same marker proteins as their parent cells. For 
example, we found that the common endothelial marker CD144 is absent on exosomes from 
human umbilical vein endothelial cells (HUVECs)(Figure 2). Recent work has further defined 
plasma EV and exosome surface marker expression by using extensive antibody profiling 
which showed that exosomes can express surface membrane markers such as CD146, 
CD4, CD3 and CD45 (Jorgensen, et al. 2015a). There is some evidence that the protein and 
RNA content of exosomes depends on the state of the source cell (de Jong, et al. 2012). 
The mechanism behind the formation of exosomes and selective packaging of proteins, 
lipids and RNA is not completely understood but is gradually becoming revealed. The 
Endosomal Sorting Complex Responsible for Transport (ESCRT) pathway does not seem to 
be required for exosome biogenesis, although some components are involved in their 
formation, particularly Alix (Baietti, et al. 2012; Raposo and Stoorvogel 2013; Trajkovic, et al. 
2008). Other molecules that are enriched in exosomes such as tetraspanins and ceramide 
have also been implicated in exosome biogenesis. For example, inhibitors of neutral 
sphingomyelinase, an enzyme involved in ceramide production, inhibits exosome production 
(Trajkovic et al. 2008). Less well understood is the mechanism of exosome release. Certain 
members of the Rab GTPase family are required for efficient release of exosomes, although 
the exact members involved appears to depend on the cell type and experimental design, 
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and may reflect different subtypes of exosomes relating to the stage (early or late) of 
endosome/MVB formation (Colombo et al. 2014). 
Purification of EVs from different bodily fluids 
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Although MVs and exosomes are produced by distinct mechanisms, their sizes overlap, and 
most isolation protocols do not isolate a pure population. Therefore, in order to evaluate 
published experiments it is important to understand what type of EV is most likely to be 
isolated by different protocols. 
A number of different protocols have been optimised for purification of different classes of 
EVs from different sources, with isolation from plasma being the best described (reviewed 
in(Lobb, et al. 2015; Witwer, et al. 2013)). The isolation of EVs from blood requires its rapid 
collection with an anti-coagulant – citrate is now generally advised (Lacroix, et al. 2012). The 
most straightforward technique for isolation of EVs involves sequential steps of 
centrifugation. After the collection of plasma by centrifugation at 1500 x g for 15 minutes, the 
supernatant contains platelet-rich plasma and EVs (MVs and exosomes). This is followed by 
a further centrifugation at 13,000 x g for 30 min to pellet the platelets, with the remaining 
EVs in the platelet poor plasma (PPP) supernatant. PPP may be snap frozen at -80 °C until 
analysis, or analysed immediately, using one of the methods outlined below. For further 
purification the PPP can be centrifuged at 17,000 x g to pellet the larger MVs, which can 
then be used for analysis. The supernatant can also be further ultracentrifuged at 100,000 x 
g to pellet the remaining EVs (Thery, et al. 2006). Although the resultant EVs are sometimes 
referred to as exosomes, this population is not completely pure and in addition to exosomes 
is likely to contain MVs and possibly lipoproteins. Density gradient centrifugation may be 
used to further purify the exosomal population (Thery et al. 2006), but recent evidence 
suggests that this still does not completely remove contamination by lipoproteins. Several 
newer methods have recently been described using commercially available columns and 
magnetic separation techniques, either directly from plasma or after initial ultracentrifugation 
to pellet the EV fraction, typically based on CD9 or CD63, but a consensus has not yet 
developed on which technique is the most promising. 
Several companies produce reagents designed to precipitate exosomes from plasma or 
tissue culture medium, though purity using these techniques is generally low, particularly 
from plasma. Affinity purification using antibodies bound to columns or beads results in 
much higher purity of EVs but by definition selectively purifies only EVs expressing the 
marker protein of interest. Size-exclusion chromatography is increasingly popular as a 
technique to purify exosomes, having been demonstrated to result in isolates relatively pure 
of contaminating lipoproteins and protein complexes (Boing, et al. 2014; Welton, et al. 2015). 
Alternatively, new approaches on the horizon include the use of antibody arrays to directly 
identify and quantify exosomes in body fluids bypassing the need for purification all together 
(Jorgensen, et al. 2015b). 
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Since the results of EV isolation procedures may vary, it is important to characterize the 
particular population being used as much as possible. 
Methods for the identification and characterization of EVs 
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The small size of EVs makes their identification a challenge, indeed until relatively recently 
they were considered to be debris and not of any functional significance. Use of electron 
microscopy enables accurate sizing of all different classes of EVs, and is the gold standard 
to demonstrate presence of EVs, however this method is time consuming, not quantitative 
and not suitable for phenotyping (Figure 3; for review of methodology see (van der Pol, et al. 
2010)). Other non-optical methods have been used, notably atomic force microscopy, which 
enables accurate size detection and can also be used in after antibody labeling of vesicles 
enabling phenotyping. Once again, however, the technique is time consuming and requires 
concentration of the sample meaning that it is not quantitative. A number of optical methods 
have been used for detection of EVs, the most widely reported of which is flow cytometry, 
however detection is limited to particle sizes above ~200 nm, so exosome analysis is not 
possible with standard configurations and techniques. However, recent exciting 
developments have enabled direct visualization and characterization of microvesicles in 
whole blood, platelet-rich and platelet-free plasma using Image stream technology 
(Headland, et al. 2014). 
A number of sophisticated protocols have been described to differentiate MVs from 
background noise during detection using this method, and standardised guidelines have now 
been published for optimised collection of plasma for detection of MVs (Lacroix et al. 2012). 
Techniques are being developed which may even allow the detection of individual exosomes 
using dedicated flow cytometers with special labelling methods (Pospichalova, et al. 2015). 
An alternative and more widespread approach is to bind exosomes to carrier latex beads, 
which are easily detectable by flow cytometry (Thery et al. 2006) (Figure 3). 
Important considerations for detection of MVs by flow cytometry are that accurate sizing and 
enumeration of the MV population may be hampered by the light scattering of small particles 
compared to larger cells, for which flow cytometers are usually used. However, inclusion of 
commercially available pre-calibrated counting beads in all samples as internal controls and 
use of sizing beads can enable standardisation of measurements between samples in the 
same study (Figure 3) – although caution should be used when directly comparing data from 
flow cytometry with other methods of counting MV. The newer generations of flow 
cytometers have been optimised to enable detection of smaller particles. The use of surface 
markers for phenotyping MV has been reviewed elsewhere (Lacroix and Dignat-George 
2012; Macey, et al. 2011). 
Flow cytometry is very useful for detection of different phenotypic markers on the surface of 
MVs and enables accurate characterisation of the source of circulating EVs in bodily fluids, 
however this technique is not suitable for detection of smaller exosomes and several 
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alternative methodologies have been developed, each with its own instrumentation. These 
include dynamic light scattering (DLS), nanoparticle tracking analysis (NTA, Figure 3) and 
tunable resistive pulse sensing (TRPS) (van der Pol et al. 2010). These methods have 
greater size discrimination compared to flow cytometry (down to below 50 nm diameter) and 
so enable quantitation of exosomes and smaller MV more efficiently (cost and time) than by 
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EM or atomic force microscopy, however, they are limited by lack of multiple laser 
capabilities to enable accurate phenotyping, as well as sometimes requiring lengthy 
purification protocols to ensure that only exosomes are quantified. Importantly, they cannot 
distinguish EVs from other particulate matter such as protein aggregates, so confirmatory 
techniques are required to validate EV presence. Raman spectroscopy has also been used 
to define EV populations. This is a highly sensitive technique for analysis of the biochemical 
composition of EVs without labelling, and can provide quantitative data, however it is very 
time consuming. Direct detection of marker proteins on exosomes is challenging using these 
techniques.   
Extracellular vesicles can transfer proteins and RNA 
The field of EV research was greatly invigorated by the demonstration that they are able to 
deliver proteins and RNA to recipient cells. The first evidence for this was obtained in 
platelets, which released tissue factor (TF), which was subsequently functionally transferred 
via microvesicles to monocytes and other cells where TF was able to exert its biological 
effects (Del Conde, et al. 2005; Scholz, et al. 2002). Microvesicles from tumour cells were 
shown to be capable of transferring a truncated, oncogenic form of the epidermal growth 
factor receptor between cells, activating signalling pathways (MAPK and Akt) and thereby 
transferring the associated transformed phenotype (Al-Nedawi, et al. 2008). Microvesicles 
can also deliver mRNA (Skog, et al. 2008). 
Exosomes can also deliver molecules into the membrane of recipient cells. This appears to 
be part of their normal function in helping to establish morphogen gradients during 
development. For example, exosomes can transfer the Notch ligand Delta-like 4 (Dll4) 
between endothelial cells, where it is incorporated into the membrane of the target 
endothelial cells, and inhibits Notch signalling altering angiogenesis (Sheldon, et al. 2010). 
Interestingly, some cytoprotective proteins have been shown to be transferred between 
cells. αB crystallin is secreted from human retinal pigment epithelium in exosomes, and 
taken up by adjacent photoreceptors, protecting them from oxidative stress (Sreekumar, et 
al. 2010). 
In a seminal paper, Valadi et al, were first to show that exosomes can also transfer mRNA 
and miRNA between cells (Valadi, et al. 2007). In this study, mast cells were demonstrated 
to transfer functional mRNAs between cells that were subsequently translated. Importantly 
when exosomes were pre-treated with RNAse and trypsin, the effect was no longer 
observed, demonstrating that the mRNA was protected within the vesicles and not simply 
associated or co-purified.  
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The profile of miRNAs contained within exosomes appears to depend on the cell type of 
origin. The miRNA profile is different in exosomes released from C2C12 myoblasts 
compared with those released by C2C12 cells once they have differentiated into myotubes 
(Forterre, et al. 2014). The miRNA profile within exosomes was also found to differ from the 
parent C2C12 cells, which indicates that there is selective sorting of miRNA into exosomes 
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(Forterre et al. 2014). The mechanism for this is only beginning to be unravelled, but 
appears to involve recognition of particular sequence motifs by sumoylated heterogeneous 
nuclear ribonucleoprotein A2B1 (hnRNPA2B1) (Villarroya-Beltri, et al. 2013). When the 
exosomes secreted by C2C12 myotubes were taken up by myoblasts they suppressed 
expression of Sirt1, potentially modulating metabolic homeostasis and the commitment of 
myoblasts during differentiation (Forterre et al. 2014). 
There is also evidence that exosomes are used by some cells in the heart to communicate 
to each other. Cardiac fibroblasts secrete exosomes that are enriched in specific miRNAs, 
including miR-21-3p. Intriguingly, this particular miRNA is a “passenger strand” miRNA 
which normally undergoes intracellular degradation and was therefore believed to be non-
functional (Bang, et al. 2014). However, when neonatal cardiomyocytes took up these 
exosomes, they increased in size indicating a hypertrophic response (Bang et al. 2014). 
Endothelial cells have also been shown to transfer miRNA via EVs, in this case transferring 
EV to smooth muscle cells after stimulation by shear stress, which is known to be 
atheroprotective (Hergenreider, et al. 2012). The EVs delivered functional miR-143/145 into 
smooth muscle cells in co-culture, which controlled the expression of target genes 
(Hergenreider et al. 2012). Importantly, when administered in vivo to ApoE(-/-) mice, they 
reduced atherosclerotic lesion formation in the aorta (Hergenreider et al. 2012). The vesicles 
in this study were referred to conservatively as “extracellular vesicles”, because a maximum 
centrifugation speed of 20,500 g was used to pellet them, and the size range of most of the 
vesicles on electron micrographs ranged between 60 and 130 nm, therefore they likely 
contained a mix of exosomes and microvesicles. 
In view of the RNA content of EVs which is related to the cell type of origin, and can alter in 
pathological settings, they have become an attractive source of biomarkers for profiling and 
identification of disease markers (Cheng, et al. 2014; Jansen, et al. 2013; Kruger, et al. 
2014), as has been reviewed elsewhere (Gaceb, et al. 2014). 
The role of EVs in diabetes and metabolic disease 
T2DM is characterized by elevated fasting plasma glucose levels combined with insulin 
resistance. The metabolic syndrome additionally comprises abdominal (central) obesity, high 
blood pressure, insulin resistance, and lipid abnormalities (Perrone-Filardi, et al. 2015). It is 
present in 34% of the population, and greatly increases the risk of heart failure (Perrone-
Filardi et al. 2015). There is accumulating evidence that EVs are elevated in these 
conditions and can contribute to some of the pathophysiology, including vascular 
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complications, inflammation and alterations in blood coagulation (recent review Lakhter 
(Lakhter and Sims 2015)). 
Exosomes and MVs from different cellular sources can be identified constitutively in plasma 
from normal individuals (Caby, et al. 2005; Raposo and Stoorvogel 2013), including MVs 
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released from monocytes, lymphocytes, endothelial cells, erythrocytes and platelets. A 
number of studies have demonstrated that the numbers of circulating MVs is increased in 
insulin-resistant patients (Jayachandran, et al. 2011), and in patients with T2DM (Diamant, 
et al. 2002; Omoto, et al. 1999). Levels are further increased in those with microvascular 
complications (Ogata, et al. 2006; Omoto et al. 1999), or secondary macrovascular CVD, 
including atherosclerosis (Diamant et al. 2002). Increased numbers of MV have also been 
linked to obesity (Stepanian, et al. 2013). Interestingly, a significant reduction in MV 
numbers has been described after calorific restriction or bariatric surgery in these patients 
(Cheng, et al. 2013). Increased EVs are also a hallmark of CVD including atherosclerosis 
(Feng, et al. 2010), hypertension (Chen, et al. 2012), and following stroke or myocardial 
infarction (D'Alessandra, et al. 2010; Kim, et al. 2012). 
The role of chronic inflammation in progression of CVD and CMD has been highlighted in a 
number of studies (reviewed in (Hansson, et al. 2015);(Lindhardsen, et al. 2015)) and 
circulating EVs are increased in many inflammatory conditions (e.g. (Daniel, et al. 2006; 
Joop, et al. 2001; Suades, et al. 2015)). Their role in propagation of endothelial pro-
inflammatory cascades is also increasingly recognized, and was first described by Mesri et 
al. They stimulated EVs in vivo in healthy volunteers by infusion of a chemotactic peptide 
and showed that these were able to induce cytokine and chemokine release from endothelial 
cells in vitro (Mesri and Altieri 1998). A number of other studies have reported similar 
findings using EVs from patients or animal models (Meziani, et al. 2010; Wang, et al. 2011). 
We have recently shown that EVs induced by long term feeding of a high fat diet in a rat 
model of insulin resistance and T2DM were able to induce VCAM-1 adhesion molecule 
expression and ROS production in rat cardiac endothelial cells in vitro (Heinrich, et al. 2015). 
The same factors that increase the risk of cardiometabolic disease are also risk factors for 
polycystic ovary syndrome (PCOS)(Daskalopoulos, et al. 2015), the most common 
endocrine disorder in women aged 18-44, affecting up to 10% of the population, and which 
leads to reduced fertility (Teede, et al. 2010). Several studies have now shown that in 
accordance with these increased risk factors, PCOS patients have increased circulating 
levels of EVs, particularly pro-coagulant platelet MVs (Koiou, et al. 2011; Koiou, et al. 2013). 
Willis et al recently measured increased numbers of circulating EVs nearing the exosome 
size range (<150 nm), with a greater percentage of annexin V+ve MV and 16 miRNA that 
were differentially expressed compared to matched controls (Willis, et al. 2014). However, a 
causal relationship has not yet been established between MVs and the other symptoms of 
PCOS which include excess androgen activity, oligo-ovulation or anovulation, and polycystic 
ovaries (Teede et al. 2010). 
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The role EVs in the function and dysfunction of healthy and diseased endothelium 
A number of studies have demonstrated a correlation between the number of circulating 
endothelial (CD31+CD41–) MVs and endothelial dysfunction in patients with coronary artery 
disease (Chen et al. 2012; Wang, et al. 2014b; Werner, et al. 2006). Similarly, in T2DM 
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patients higher numbers of endothelial MVs correlate with impaired endothelium function, as 
determined by the measurement of flow mediated dilatation in the brachial artery (Feng et al. 
2010). In addition to their levels increasing with endothelial dysfunction, MVs may also have 
a direct effect on endothelial function. MVs isolated from T2DM patients by centrifugation 
have been shown to impair shear stress induced dilatation of mouse mesenteric arteries 
(Martin, et al. 2004) whilst aortic ring experiments have shown that endothelial derived EVs 
(obtained by ultracentrifugation at 100,000 x g) decrease nitric oxide (NO) and increase 
reactive oxygen species production, as well as impairing acetylcholine-mediated 
vasorelaxation (Brodsky, et al. 2004). Consequently, microvesicles have gained some 
notoriety as potentially detrimental factors contributing to cardiovascular disease. 
On the other hand, EVs have also been observed to have some beneficial effects, 
particularly with regards to the stimulation of endothelial proliferation, migration and tube 
formation in vitro (Deregibus, et al. 2007; Jansen et al. 2013)(Vrijsen, et al. 2010). This effect 
has been observed with EVs isolated from apoptotic endothelial cells (Deregibus et al. 2007; 
Jansen et al. 2013) (and therefore presumably containing many apoptotic vesicles), as well 
as with more pure populations of MVs isolated from platelets (Brill, et al. 2005; Kim, et al. 
2004), from endothelial progenitor cells (Deregibus et al. 2007; Vrijsen et al. 2010), or from 
ischemic muscle (Leroyer, et al. 2009). Exosomes isolated from cardiomyocyte progenitor 
cells (Vrijsen et al. 2010) or the conditioned medium of bone marrow CD34+ stem cells 
(Sahoo, et al. 2011) have been shown to have a similar effect on endothelial cell proliferation 
and migration. 
EVs can also stimulate endothelial repair. For example, endothelial EVs were isolated by 
centrifugation from human coronary artery endothelial cells undergoing apoptosis. When 
administered to mice in which a region of endothelium had been denuded, these EVs were 
found to be capable of repairing the endothelium via delivery of miR-126 (Jansen et al. 
2013). It is significant, however, that this effect was abrogated in EVs isolated from cells 
which had been grown under hyperglycaemic conditions in vitro or isolated from patients 
with T2DM, since this suggests that this reparative property of EVs is altered by diabetes 
and may contribute to continued vascular damage and dysfunction (Jansen et al. 2013). 
Similarly, exosomes from the cardiomyocytes of non-diabetic rats were founds to be pro-
angiogenic, stimulating endothelial proliferation, migration and tube formation in vitro, while 
those isolated from the cardiomyocytes of diabetic rats had the opposite effect (Wang, et al. 
2014a).In this example, the detrimental effect was attributed to exosomal transfer of miR320 
and the down-regulation of its target genes (IGF-1, Hsp20 and Ets2) (Wang et al. 2014a). 
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Various additional mechanisms have been implicated in the stimulatory effect of exosomes 
on endothelial cells. Platelet MVs appear to activate pro-angiogenic ERK and PI3K/Akt 
pathways (Brill et al. 2005; Kim et al. 2004) and may contain a contain a lipid growth factor 
(Kim et al. 2004), while EVs from endothelial progenitor cells appear to transfer mRNAs that 
activate PI3K/AKT and eNOS signaling in the recipient endothelial cells (Deregibus et al. 
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2007). The transfer of miR-214 has also been proposed to mediate induction of 
angiogenesis by endothelial exosomes by suppressing the expression of ATM in recipient 
cells (van Balkom, et al. 2013). Endothelial cells also communicate atheroprotective stimuli 
to smooth muscle cell via the transmission of miR-143/145 via EVs (Hergenreider et al. 
2012). In this study, EV were purified by centrifugation at 20,500 g for 1 h, resulting in 
vesicles that were mostly between 60 and 130 nm. 
In some cases, exosomes can also suppress hyperproliferative pathways such as those that 
contribute to hypoxia-induced pulmonary hypertension. Here, the beneficial effect of 
mesenchymal stromal cells was shown to be mediated by the release of exosomes which 
suppressed hyperproliferative pathways including those mediated by STAT3 and the miR-17 
superfamily, in addition to increasing lung levels of miR-204 (Lee, et al. 2012). 
Recently, pressure overload or stretch was shown to cause the release from cardiomyocytes 
of exosomes containing functional angiotensin II type 1 receptors, which are able to be 
transferred to skeletal muscle, mesenteric resistance vessels and cardiomyocytes, 
conferring responsiveness to angiotensin II (Pironti, et al. 2015). This exciting data suggests 
that exosomes may contribute to the in vivo tissue distribution of cell surface receptors such 
as angiotensin II, with functional consequences for the cardiovascular system. 
The role of EVs in coagulopathies  
When EVs were first described by Peter Wolf they were referred to as “platelet dust” (Wolf 
1967) because they were thought not to be functionally significant. Despite there being some 
reports to the contrary (Tushuizen, et al. 2012), numerous studies have shown that platelet 
EVs are procoagulant due to the exposure of negatively charged PS which can enhance clot 
formation (for review see (Hargett and Bauer 2013)). Indeed, platelet EVs have more binding 
sites for the factors involved in the clotting cascade than do activated platelets themselves 
(Sinauridze, et al. 2007). More recent studies have revealed the presence of tissue factor 
(TF) on the surface of endothelial- and monocyte-derived EVs (Breitenstein, et al. 2010), as 
well as P-selectin glycoprotein ligand-1 (PSGL-1) which can bind to P-selectin on the 
surface of activated platelets and become incorporated into the clot (Falati, et al. 2003). 
Other receptors including glycoprotein IIb/IIIa (Sommeijer, et al. 2005), factor VIII, factor Va 
(Nomura, et al. 1993) and protein disulphide isomerase (Raturi, et al. 2008) may also be 
present on the surface of EVs and participate in clot formation and thrombosis.  
In addition to hyperglycemia, hyperinsulinemia can cause an increase in procoagulant TF-
positive MVs (Boden and Rao 2007), and MVs are elevated in otherwise-healthy individuals 
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with signs of metabolic syndrome (Agouni, et al. 2008; Ueba, et al. 2008). A correlation 
between circulating endothelial microparticles (MVs) and cardiometabolic risk factors 
(particularly dyslipidaemia), was also detected in the Framingham Heart Study cohort 
(Amabile, et al. 2014). The presence of hypertension, elevated triglycerides, and metabolic 
syndrome all increased circulating MVs, but dyslipidaemia had the most severe effect. 
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Obesity has also been correlated with increased circulating endothelial MVs in children 
(Gunduz, et al. 2012). These increases may contribute to the disease, since MVs from 
individuals with metabolic syndrome have been shown to impair endothelium-dependent 
relaxation and decrease endothelial NO synthase expression when injected into mice 
(Agouni et al. 2008). Other cardiovascular risk factors such as uremia may also correlate 
with increased numbers of platelet MVs which may trigger thrombosis (Ando, et al. 2002). 
Elevated uric acid in chronic renal failure patients may also contribute to their increased risk 
of cardiovascular events (Faure, et al. 2006). 
Tsimerman et al measured increased numbers of pro-coagulant TF-positive EVs in patients 
with T2DM, but MV coagulability was significantly increased only in those who also had 
macrovascular complications (foot ulcers and coronary artery disease) (Tsimerman, et al. 
2011). EVs were isolated and evaluated for their ability to induce tube formation in 
endothelial cells in vitro. Endothelial tube formation was stimulated by MVs from healthy 
controls, but was defective when incubated with MVs from patients with macrovascular 
complications (Tsimerman et al. 2011).  
Thus, hyperglycemia, dyslipidaemia and hyperinsulinemia as well as hyperuricemia and 
uremia appear to contribute to cardiometabolic disease via the procoagulant activity of MVs, 
but also due to their diminished ability to support endothelial function. 
EVs as a potential therapy for cardiometabolic disease 
The heart is essentially terminally differentiated, meaning that there is very little division of 
cardiomyocytes after injury (e.g. IR), and instead those that remain tend to undergo a 
compensatory increase in size. The possibility of renewing the cardiomyocytes by stem cell 
therapy has been intensively investigated for a number of years, however, the results of this 
approach have been largely disappointing. Some improvements in cardiac function have 
been observed after stem cell therapy, although this is generally acknowledged to occur in 
the absence of new cardiomyocyte formation. Interestingly, similar levels of benefit could 
also be obtained experimentally after injecting medium that had been conditioned by stem 
cells. It was therefore proposed that stem cells release cytokines, growth factors and other 
proteins in a “paracrine” manner to improve survival and function of cardiomyocytes (Kim, et 
al. 2014; Menasche 2014; Yoon, et al. 2005).  
In 2010, it was shown that exosomes purified from the conditioned medium of human ESC-
derived mesenchymal stem cells (ESC-MSC) by HPLC size-exclusion fractionation, could 
protect the heart both in vitro and in vivo (Lai, et al. 2010). Cardiac function after 28 days 
 25 
was also improved (Arslan, et al. 2013). An increase in the activity of cardioprotective 
kinases Akt and GSK3α/β was observed 1 h after exosome administration until the following 
day (Arslan et al. 2013). These kinases are known to be highly cardioprotective (Hausenloy, 
et al. 2005). In another study, exosomes were isolated from MSC cells overexpressing 
GATA4, and these also restored cardiac contractile function and reduced infarct size when 
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injected into rat hearts at the time of infarction (Yu, et al. 2014). Protection was attributed to 
an increase in the treated hearts of miR-19a, which targets PTEN, indirectly increasing Akt 
and ERK activation. However, with such experiments it is difficult to ascertain whether the 
miR-19a was transferred from the MSC exosomes or was a transcriptional response of the 
myocardium to the treatment (Yu et al. 2014). The ability to activate protective pathways 
does not appear to be restricted to exosomes, since microvesicles derived from human adult 
mesenchymal stem cells were also able to protect the kidney against ischaemia and 
reperfusion injury (Gatti, et al. 2011).  
MSC are not the only type of stem cell that has been shown to release exosomes with 
beneficial cardiovascular effects. Intramyocardial injection of exosomes from murine cardiac 
progenitor cells (CPCs) reduced apoptosis after ischaemia and reperfusion (Chen, et al. 
2013). In this study, however, exosomes were isolated by precipitation with polyethylene 
glycol (PEG) (Chen et al. 2013), which raises some uncertainty about the effects that the 
PEG might have itself. In another study EVs were isolated from CPCs derived from atrial 
appendage explants from patients undergoing heart valve surgery (Barile, et al. 2014). 
Injection of these CPCs-EVs into the hearts of rats subject to permanent coronary artery 
ligation reduced cardiomyocyte apoptosis and scar size, increased the amount of viable 
tissue in the infarct area, increased blood vessel density, and prevented the impairment of 
ventricular function between day 2 and day 7 (Barile et al. 2014). In contrast, exosomes 
isolated from normal human dermal fibroblasts exhibited no benefit, suggesting that effects 
depend on cell type of origin (Barile et al. 2014). Intramyocardial injection of exosomes 
isolated from CPCs that had been exposed to hypoxia for 12 h improved cardiac function 
and also reduced fibrosis 21 days (Gray, et al. 2015). The exosomes released after hypoxia 
had an altered miRNA content, and co-regulated miRNA with a beneficial profile were 
identified (Gray et al. 2015). Although cardiac endothelial cells and fibroblasts took up 
fluorescently stained exosomes in vitro, uptake was minimal in primary rat cardiomyocytes 
(Gray et al. 2015), suggesting either that they deliver miRNA directly to the former cells 
types, or that they interact with surface receptors on cardiomyocytes without delivering 
miRNA intracellularly. Thus, the exact mechanism of functional benefit conferred by CPC-
EVs remains unclear. 
When a nonviral mini-circle plasmid carrying HIF1, a transcription factor that mediates 
adaptive responses to ischemia, was delivered into the endothelium of ischemic mouse 
myocardium, these cells were found to release exosomes with a higher content of miR-126 
and miR-210. These exosomes could be taken up by CPCs administered to the heart, 
leading to the activation of pro-survival kinases and to a switch towards glycolysis. This 
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resulted in them having an increased tolerance against hypoxic stress (Ong, et al. 2014) and 
suggests the interesting possibility that endothelial cells can support CPC survival by 
exosomal transfer of miRNA. 
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An attractive aspect of using EVs for therapy is the potential for altering their cargo to 
augment their protective capabilities. In a study by Mackie et al, CD34+ cells or their 
exosomes showed no benefit after injection into ischaemic mouse hearts. However, CD34+ 
cells were then genetically modified to to express the sonic hedgehog (Shh) protein, in order 
to enhance the angiogenic quality of CD34+ cells. When CD34+Shh cells were injected into 
the infarct border zone in mice, infarct size was reduced, border zone capillary density was 
increased, and ventricular dilation and cardiac function were improved 4 weeks later 
(Mackie, et al. 2012). In vitro studies in cells were performed to demonstrate that Shh was 
released from the CD34+Shh cells in exosomes, and could be transferred to recipient cells 
and (modestly) activate transcription. Injection of the exosomes from CD34+Shh cells had 
the same benefit, though exosomes from CD34+ cells wihout Shh showed no benefit 
(Mackie et al. 2012).  
Strikingly, it has been shown that there are on the order of 1010 EVs per ml present in the 
blood of all individuals, after isolation using the technique of differential ultracentrifugation, 
(Caby et al. 2005), and these could potentially be continually delivering different miRNA or 
receptor-ligand mediated signals to the heart. This possibility was addressed by isolating 
plasma exosomes from rats or healthy individuals by differential ultracentrifugation and 
testing whether they were cardioprotective in in vitro, ex vivo and in vivo models of IR 
(Vicencio, et al. 2015). Indeed, exosomes from plasma were strongly cardioprotective, 
activating the cardioprotective ERK1/2 kinase and reducing infarct size (Vicencio et al. 
2015). Plasma exosomes were similarly protective in an isolated perfused rat heart model 
and in primary cardiomyocytes, suggesting a direct effect of the exosomes at the plasma 
membrane level, although interestingly exosomes did not appear to be taken up by the 
cardiomyocytes but they were endocytosed by endothelial cells (Vicencio et al. 2015). This 
study also showed that the number of exosomes in the plasma was increased by short (5 
min) cycles of limb IR. This manipulation is under investigation of a means of inducing 
protection of the heart and other organs via a phenomenon known as “remote ischaemic 
preconditioning (RIC)” (Hausenloy and Yellon 2008). As yet, the mechanism of RIC is 
unknown although evidence for several mediators has been presented, including SDF-1α 
and Il-10 (Cai, et al. 2012; Davidson, et al. 2013). As vehicles able to deliver multiple signals 
between cells, EVs had been proposed as possible candidates for carriers of the 
cardioprotective factor released by RIC (Yellon and Davidson 2014). A study by Giricz et al. 
suggested that this may be the case, since RIC was not effective when EVs were removed 
from medium containing the factor (Giricz, et al. 2014). However, in a dose-response 
experiment conducted using primary adult rat cardiomyocytes the EVs released after RIC 
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were found not to be significantly more protective that exosomes from baseline (Vicencio et 
al. 2015). 
On the other hand, the observation that plasma EVs themselves were cardioprotective is 
important and may suggest that they signal continuously to the heart, modulating the 
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protective state. Protection was shown to involve HSP70 in the exosome membrane, which 
binds to TLR4 on cardiomyocytes, activating ERK1/2, p38MAPK and downstream 
phosphorylation of the small heat shock protein HSP27 (Vicencio et al. 2015). TLR4 is part 
of the innate immune system, and strong activation by its ligands from bacteria leads to a 
cell damage response and can cause cell death. However, mild activation is known to be 
protective (Mathur, et al. 2011; Zhang, et al. 2013). Other studies have suggested a link 
between body fluid exosomes and TLR-dependent signaling pathways, possibly mediating 
immunosuppressive and anti-inflammatory pathways (Bretz, et al. 2013; Zhang, et al. 2014). 
 
Conclusion 
With T2DM reaching epidemic proportions and cardiovascular disease being the major 
cause of death worldwide, novel therapeutic strategies are urgently needed to offer cell and 
tissue repair mechanisms to the myocardium and also diseases characterized by endothelial 
dysfunction. EVs including MVs and exosomes have emerged over the past decade to 
attract immense interest due to their potential either as biomarkers or mediators of disease. 
Increased MVs in plasma can be observed in patients with insulin resistance, T2DM, 
atherosclerosis and also after stroke or myocardial infarct. MVs have been also described as 
mediators of inflammation and to be involved in the pro-coagulant actions of platelets. The 
protein or RNA cargo of EVs offers additional potential not only for their use as biomarkers 
but also for their use as vehicles for delivering bioactives. As such, they offer the capability 
of delivering multiple signals to target tissues. Stem cells are the best-explored example of 
cells that deliver miRNA via exosomes with beneficial effects on the heart, kidneys and the 
endothelium. Exosomes and MVs have also been implicated in protecting the heart from 
infarction and have been proposed as potential mediators of ischaemic conditioning. EVs 
therefore represent one of the most exciting and promising research areas for the endocrine 
community. However, there is still much left to understand regarding the mechanisms of EV 
formation and their specific targeting to a selective tissue. Although current research has 
provided valuable insight to the mechanisms of EV release, we are only beginning to 
understand mechanisms of RNA/protein loading into exosomes for instance, and exploring 
these mechanisms is essential to design efficient therapeutical strategies involving EVs.  
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Figure legends 
Figure 1 
(A) Timeline (1956-2014) of the publications referring to extracellular vesicles (black line), 
microvesicles (blue line) and exosomes (red line). (B) Schematic representation of the 
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mechanisms of formation of microvesicles, exosomes and apoptotic bodies. Microvesicles 
(0.2 – 2.0 µm) originate via budding and shedding from the plasma membrane of cells and 
therefore may contain specific surface markers from the cell of origin. Exosomes (50 - 100 
nm) on the other hand originate intracellularly through a sorting pathway involving 
intermediate organelles such as the early endosome and a late multivesicular body, which 
fuses with the plasma membrane to release exosomes via exocytosis. Apoptotic bodies (1 - 
2 µm) originate via blebbing of the plasma membrane.  
Figure 2 
 
The endothelial cells marker CD144 is absent from exosomes isolated from HUVEC 
endothelial cells (A), despite being detectable on the parent cells (B). HUVEC cells or 
HUVEC exosomes bound to 4 μm beads were labelled with anti-CD144 and fluorescent 
secondary antibody, before fluorescent detection using a BD AccuriC6 flow cytometer. 
 
Figure 3 
Flow cytometry (FCM) allows direct analysis of microvesicles (MVs) and indirect 
(conjugated) analysis of exosomes. Nanoparticle tracking analysis (NTA) is the preferred 
technique for EV quantitation. Electron microscopy (EM) is the golden standard for EV 
visualization. (A) Direct flow cytometric analysis of MVs in plasma of rats fed chow or high 
fat diets (HFD; Heinrich et al. 2015) after staining for phosphatidyl serine exposure (Annexin 
V PE-Cy7.7) and CD106 (PE) to determine MV release from activated endothelial cells. 
Enumeration beads (red) and 1,1 μm sizing beads (green) were added as internal controls. 
(B) NTA of MVs from rats fed chow or HFD. (C) Indirect flow cytometric analysis of 
exosomes bound to aldehyde sulphate beads (4 μm) after staining for the tetraspannin 
CD63 and surface HSP70 (Vicencio et al. 2015). (D) NTA of human plasma exosomes 
isolated via ultraceintrifugation (black line) or using the Exo-spinTM (Cell Guidance Systems) 
commercial kit (red line). (E) Electron micrograph of MVs and exosomes.  
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